Loading stock data…
Cybin Inc (HELP)
$6.88+0.40 (+6.17%)
Market ClosedLast close Jun 29
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cybin D/B/A Helus Pharma in the Healthcare sector is trading at $6.88 with a market capitalization of $206M. Wall Street consensus targets $41.98 (8 analysts), implying a +510.1% move over the next 12 months. The stock is currently 30% below its 52-week high of $9.83, remaining 15.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +510.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$41.21M↓ | -$28.89M↓ | -$24.62M↑ | -$33.27M↓ | -$22.39M |
| Net Income | -$42.67M↓ | -$33.72M↓ | -$24.61M↑ | -$30.58M↓ | -$7.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in pha...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$205.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.03%
Volume
Today's trading volume
1.74M
Recent News
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?
In June 2026, Helus Pharma reported that enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder had surpassed 86%, while Cybin Inc. completed a US$50.00 million follow-on offering of 10,309,280 common shares at US$4.85 each. This combination of late-stage clinical progress for a compound with Breakthrough Therapy Designation and fresh equity capital raises important questions about Cybin’s future positioning in psychedelic-based mental health...
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector SNDL Reported “Particularly Challenging” First Quarter 2026 Financial and Operational Results Vireo Growth Accelerated Expansion with FLUENT Acquisition, Cementing its Florida Ambitions Aurora Cannabis Expanded Global Medical Portfolio with New International Product Launches Key Takeaways; Psychedelic Sector Silo Pharma Sees Momentum as U.S. Accelerates Psychedelic PTSD Treatments Helus Pharma Expanded Veteran […]
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
Earlier this month, Helus Pharma (operating as Cybin) reshaped its leadership by appointing interim CEO Eric So, expanding medical leadership with Dr. Ken Kramer as Senior Vice President of Medical Affairs, and adding renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. By bringing together high-profile figures in biotechnology, CNS drug development, and medical affairs, Helus Pharma is signaling an emphasis on clinically rigorous development of its...
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.